Anissa A Widjaja1, Brijesh K Singh1, Eleonora Adami1, Sivakumar Viswanathan1, Jinrui Dong1, Giuseppe A D'Agostino1, Benjamin Ng2, Wei Wen Lim2, Jessie Tan2, Bhairav S Paleja3, Madhulika Tripathi1, Sze Yun Lim4, Shamini Guna Shekeran1, Sonia P Chothani1, Anne Rabes5, Martina Sombetzki5, Eveline Bruinstroop1, Lio Pei Min4, Rohit A Sinha6, Salvatore Albani3, Paul M Yen1, Sebastian Schafer2, Stuart A Cook7. 1. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore. 2. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore. 3. Translational Immunology Institute, SingHealth/Duke-NUS Academic Medical Centre, Singapore. 4. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore. 5. Department of Tropical Medicine and Infectious Diseases, University Medical Center, Rostock, Germany. 6. Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. 7. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore; National Heart and Lung Institute, Imperial College London, London, UK; MRC-London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK. Electronic address: stuart.cook@duke-nus.edu.sg.
Abstract
BACKGROUND & AIMS: We studied the role of interleukin 11 (IL11) signaling in the pathogenesis of nonalcoholic steatohepatitis (NASH) using hepatic stellate cells (HSCs), hepatocytes, and mouse models of NASH. METHODS: We stimulated mouse and human fibroblasts, HSCs, or hepatocytes with IL11 and other cytokines and analyzed them by imaging, immunoblot, and functional assays and enzyme-linked immunosorbent assays. Mice were given injections of IL11. Mice with disruption of the interleukin 11 receptor subunit alpha1 gene (Il11ra1-/-) mice and Il11ra1+/+ mice were fed a high-fat methionine- and choline-deficient diet (HFMCD) or a Western diet with liquid fructose (WDF) to induce steatohepatitis; control mice were fed normal chow. db/db mice were fed with methionine- and choline-deficient diet for 12 weeks and C57BL/6 NTac were fed with HFMCD for 10 weeks or WDF for 16 weeks. Some mice were given intraperitoneal injections of anti-IL11 (X203), anti-IL11RA (X209), or a control antibody at different timepoints on the diets. Livers and blood were collected; blood samples were analyzed by biochemistry and liver tissues were analyzed by histology, RNA sequencing, immunoblots, immunohistochemistry, hydroxyproline, and mass cytometry time of flight assays. RESULTS: HSCs incubated with cytokines produced IL11, resulting in activation (phosphorylation) of ERK and expression of markers of fibrosis. Livers of mice given injections of IL11 became damaged, with increased markers of fibrosis, hepatocyte cell death and inflammation. Following the HFMCD or WDF, livers from Il11ra1-/- mice had reduced steatosis, fibrosis, expression of markers of inflammation and steatohepatitis, compared to and Il11ra1+/+ mice on the same diets. Depending on the time of administration of anti-IL11 or anti-IL11RA antibodies to wild-type mice on the HFMCD or WDF, or to db/db mice on the methionine and choline-deficient diet, the antibodies prevented, stopped, or reversed development of fibrosis and steatosis. Blood samples from Il11ra1+/+ mice fed the WDF and given injections of anti-IL11 or anti-IL11RA, as well as from Il11ra1-/- mice fed WDF, had lower serum levels of lipids and glucose than mice not injected with antibody or with disruption of Il11ra1. CONCLUSIONS: Neutralizing antibodies that block IL11 signaling reduce fibrosis, steatosis, hepatocyte death, inflammation and hyperglycemia in mice with diet-induced steatohepatitis. These antibodies also improve the cardiometabolic profile of mice and might be developed for the treatment of NASH.
BACKGROUND & AIMS: We studied the role of interleukin 11 (IL11) signaling in the pathogenesis of nonalcoholic steatohepatitis (NASH) using hepatic stellate cells (HSCs), hepatocytes, and mouse models of NASH. METHODS: We stimulated mouse and human fibroblasts, HSCs, or hepatocytes with IL11 and other cytokines and analyzed them by imaging, immunoblot, and functional assays and enzyme-linked immunosorbent assays. Mice were given injections of IL11. Mice with disruption of the interleukin 11 receptor subunit alpha1 gene (Il11ra1-/-) mice and Il11ra1+/+ mice were fed a high-fat methionine- and choline-deficient diet (HFMCD) or a Western diet with liquid fructose (WDF) to induce steatohepatitis; control mice were fed normal chow. db/db mice were fed with methionine- and choline-deficient diet for 12 weeks and C57BL/6 NTac were fed with HFMCD for 10 weeks or WDF for 16 weeks. Some mice were given intraperitoneal injections of anti-IL11 (X203), anti-IL11RA (X209), or a control antibody at different timepoints on the diets. Livers and blood were collected; blood samples were analyzed by biochemistry and liver tissues were analyzed by histology, RNA sequencing, immunoblots, immunohistochemistry, hydroxyproline, and mass cytometry time of flight assays. RESULTS: HSCs incubated with cytokines produced IL11, resulting in activation (phosphorylation) of ERK and expression of markers of fibrosis. Livers of mice given injections of IL11 became damaged, with increased markers of fibrosis, hepatocyte cell death and inflammation. Following the HFMCD or WDF, livers from Il11ra1-/- mice had reduced steatosis, fibrosis, expression of markers of inflammation and steatohepatitis, compared to and Il11ra1+/+ mice on the same diets. Depending on the time of administration of anti-IL11 or anti-IL11RA antibodies to wild-type mice on the HFMCD or WDF, or to db/db mice on the methionine and choline-deficient diet, the antibodies prevented, stopped, or reversed development of fibrosis and steatosis. Blood samples from Il11ra1+/+ mice fed the WDF and given injections of anti-IL11 or anti-IL11RA, as well as from Il11ra1-/- mice fed WDF, had lower serum levels of lipids and glucose than mice not injected with antibody or with disruption of Il11ra1. CONCLUSIONS: Neutralizing antibodies that block IL11 signaling reduce fibrosis, steatosis, hepatocyte death, inflammation and hyperglycemia in mice with diet-induced steatohepatitis. These antibodies also improve the cardiometabolic profile of mice and might be developed for the treatment of NASH.
Authors: Riley D Metcalfe; Kaheina Aizel; Courtney O Zlatic; Paul M Nguyen; Craig J Morton; Daisy Sio-Seng Lio; Heung-Chin Cheng; Renwick C J Dobson; Michael W Parker; Paul R Gooley; Tracy L Putoczki; Michael D W Griffin Journal: J Biol Chem Date: 2020-04-24 Impact factor: 5.157
Authors: Jin Zhou; Brijesh K Singh; Jia Pei Ho; Andrea Lim; Eveline Bruinstroop; Kenji Ohba; Rohit A Sinha; Paul M Yen Journal: Autophagy Date: 2021-03-18 Impact factor: 16.016
Authors: Ce Li; Zhenzi Peng; Yizhou Wang; Gloria Lam; Nicholas Nissen; Jie Tang; Xiaopu Yuan; Michael Lewis; Mark I Greene; Stephen J Pandol; Qiang Wang Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-27 Impact factor: 4.052
Authors: Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos Journal: Nat Rev Gastroenterol Hepatol Date: 2021-07-01 Impact factor: 46.802